Hybio Pharmaceutical Co., Ltd.

Shenzhen Stock Exchange 300199.SZ

Hybio Pharmaceutical Co., Ltd. Return on Capital Employed (ROCE) for the year ending December 31, 2023: -20.96%

Hybio Pharmaceutical Co., Ltd. Return on Capital Employed (ROCE) is -20.96% for the year ending December 31, 2023, a -101.76% change year over year. Return on capital employed assesses profitability against invested capital; higher ROCE signals efficient capital use.
  • Hybio Pharmaceutical Co., Ltd. Return on Capital Employed (ROCE) for the year ending December 31, 2022 was -10.39%, a -376.21% change year over year.
  • Hybio Pharmaceutical Co., Ltd. Return on Capital Employed (ROCE) for the year ending December 31, 2021 was 3.76%, a 120.34% change year over year.
  • Hybio Pharmaceutical Co., Ltd. Return on Capital Employed (ROCE) for the year ending December 31, 2020 was -18.49%, a 19.73% change year over year.
  • Hybio Pharmaceutical Co., Ltd. Return on Capital Employed (ROCE) for the year ending December 31, 2019 was -23.03%, a -289.78% change year over year.
Key data
Date Return on Capital Employed (ROCE) Interest Coverage Ratio Debt to Equity Ratio Return on Common Equity
Market news
SV Wall Street
Shenzhen Stock Exchange: 300199.SZ

Hybio Pharmaceutical Co., Ltd.

CEO Ms. Yu Pinxiang
IPO Date April 7, 2011
Location China
Headquarters Hanyu Biological Park, No. 37
Employees 895
Sector Healthcare
Industries
Pharmaceuticals Biotechnology Chemicals & Advanced Materials Personal Care Pet Food Petrochemicals Plastics Vaccines
Description

Hybio Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of therapeutic peptides API and polypeptide drugs in China and internationally. The company provides liraglutide, semaglutide and exenatide for diabetes; terlipressin, desmopressin and linaclotide for digestive tract and metabolic system; ganirelix, cetrorelix and atosiban for obstetrics and gynecology, etc; customized peptides; working standards for the peptide APIs and related impurities, to facilitate your project in an all-round way; CRO services; and platform for CDMO services, which includes peptide API synthesis and purification process development, finish dosage form development, reference standard preparation and qualification, impurity and product quality study and analysis, GMP system meeting EU and FDA standard, international and Chinese regulatory and dossier support, etc. Hybio Pharmaceutical Co., Ltd. was founded in 1998 and is headquartered in Shenzhen, China.

StockViz Staff

February 2, 2025

Any question? Send us an email